University Hospital Rigshospitalet
- Address
- lock Available on a paid plan
University Hospital Rigshospitalet - Infectious Disease Research
University Hospital Rigshospitalet is actively engaged in cutting-edge clinical research focused on emerging infectious diseases and their management. The center demonstrates particular expertise in studying novel therapeutic interventions for patients with acute viral infections who face elevated risk of disease progression.
- COVID-19 treatment strategies for high-risk outpatient populations
- Antiviral therapeutic development and evaluation
- Prevention of severe disease progression in vulnerable patient groups
The institution's research portfolio emphasizes the evaluation of investigational antiviral agents in non-hospitalized settings, with special attention to high-risk patient populations including adults and adolescents. This focus on early intervention strategies reflects the center's commitment to preventing disease escalation and reducing the burden of severe infectious disease complications through evidence-based clinical trials.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Pfizer Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Rigshospitalet
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Double-Blind Study of Ibuzatrelvir Versus Placebo in Non-Hospitalized Adults and Adolescents with COVID-19 at High Risk for Severe Illness | Pfizer Inc. | Phase III | Recruiting | Jul 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| IBUZATRELVIR | 1 | Unknown | 2025-07-28 | 2025-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.